Latest Market News

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

xReality Group (XRG) reports a landmark FY25 with 36% revenue growth driven by its Operator XR platform and a major US law enforcement contract. The company’s strategic shift towards immersive training technology signals robust momentum into FY26.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.

Gathid Ltd reported a 142% surge in revenue for FY25 driven by its expanding software business, despite a continuing operations loss and ongoing dispute over the RightCrowd sale proceeds.

xReality Group Limited reported a 36.3% revenue increase to $13.96 million for FY2025, driven by strong Enterprise segment growth, while narrowing its net loss to $3.14 million. Despite challenges in Entertainment revenue and asset pressures, the company maintains a positive cash flow outlook.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

Ovanti Limited’s FY2025 results reveal a modest revenue dip but a sharp 61% rise in net loss, driven by a significant impairment charge. The company’s capital base strengthened despite ongoing losses, with no dividends declared.

AVADA Group Limited reported a statutory net loss of $17.6 million for FY25, driven by impairments and challenging trading conditions, while completing a major business transformation aimed at future growth.

ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.